Drug intelligence / Profile preview

NT-MnOL-Gd NC

Development stage: Preclinical
Lead developer: Washington University School of Medicine
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

**NT-MnOL-Gd NC** is a non-targeted mixed manganese-gadolinium paramagnetic nanocolloid developed as an experimental **T1-weighted magnetic resonance imaging contrast agent**. It comprises a manganese oleate nanocolloid core with surface-associated gadolinium chelate and lacks the αvβ3-integrin-targeting ligand present on the related targeted formulation. In hyperlipidemic rabbit studies of atherosclerosis, it was used as a non-targeted comparator and showed less aortic plaque accumulation than αvβ3-targeted MnOL-Gd nanocolloid. Its paramagnetic manganese and gadolinium components shorten the longitudinal relaxation time of nearby water protons, increasing T1-weighted MR signal.

Other names: non-targeted manganese oleate-gadolinium nanocolloid

Beyond the preview

Go deeper on NT-MnOL-Gd NC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NT-MnOL-Gd NC.

Explore the full profile